<p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;"><span style="font-family: 함초롬바탕; letter-spacing: 0pt;"><span style="font-family: 돋움;">「국민건강보험 요양급여의 기준에 관한 규칙」 제5조 제4항의 규정에 따른 「암환자에게 처방·투여하는 약제에 대한 요양급여의 적용기준 및 방법에 관한 세부사항」을 붙임과 같이 개정(건강보험심사평가원 공고 제2023-17호, 2023.2.1. 시행)함을 알려드리니 관련 업무에 참고하시기 바랍니다.</span></span><span style="font-family: 함초롬바탕; letter-spacing: 0pt;"></span></p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;"> </p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">□ 항암요법 개정내역</p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;"> </p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">  ○ 신설</p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">    - 급성골수성백혈병에 ‘venetoclax + decitabine’ 병용요법(1차) 신설</p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">    - 급성골수성백혈병에 ‘venetoclax + azacitidine’ 병용요법(1차) 신설<br></p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;"> </p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">  ○ 변경</p> <p style="margin-right: 0px; margin-left: 0px; padding: 0px; border: 0px; font-size: 16px; line-height: 1.7; font-family: 'Noto Sans KR', sans-serif; color: rgb(51, 51, 51); box-sizing: border-box; letter-spacing: -0.8px; word-break: keep-all;">    - 기타 암(다발성 캐슬만병)에 ‘siltuximab’ 반응평가 기준 추가</p>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

닫기